Scholarlink

<p>Cancer-associated fibroblasts (CAFs) represent a major structural component of solid tumors and play crucial roles in cancer progression and drug resistance. However, their developmental origin, differentiation trajectory, and therapeutic potential remain poorly defined. Using advanced approaches—including inducible genetic lineage tracing, single-cell RNA sequencing, and spatial transcriptomic profiling—we identified a population of Cd34<sup>+</sup>Pi16<sup>+</sup> fibroblast progenitors (Cd34<sup>+</sup> CAFs) in both melanoma and gastric cancer. We delineated their differentiation trajectory toward Acta2<sup>+</sup> CAFs, driven by the upregulation of the transcription factor Foxs1. This work establishes the developmental origin of Acta2<sup>+</sup> CAFs and experimentally validates the <i>Cd34</i><sup>+</sup> to <i>Acta2</i><sup>+</sup> transition. By reverse-matching the transcriptional signatures of Acta2<sup>+</sup> CAF differentiation with the CMap/LINCS L1000 drug perturbation database, we identified four small-molecule candidates predicted to inhibit tumor-induced <i>Foxs1</i> upregulation. These compounds effectively suppressed Cd34<sup>+</sup> CAF differentiation, maintaining the progenitor-like Cd34<sup>+</sup> state. Collectively, this study proposes a novel antitumor strategy that targets CAF lineage development to restrain tumor progression.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Foxs1-mediated transformation of CD34+ fibroblast to myCAFs promotes tumor growth

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月4日

查看全文
  • Junyao Yang,
  • Ting Chen,
  • Run Zhang,
  • Jing Xu,
  • Xinghe Zhao,
  • Mei Yang,
  • Zheyi Chen,
  • Shasha Sun,
  • Xiaocui Chen,
  • Shuqiong Zhang,
  • Liujun Jiang,
  • Yingxia Zheng,
  • Yanhua Hu,
  • Qingbo Xu,
  • Wei Lin,
  • Lisong Shen,
  • Li Zhang

摘要

Cancer-associated fibroblasts (CAFs) represent a major structural component of solid tumors and play crucial roles in cancer progression and drug resistance. However, their developmental origin, differentiation trajectory, and therapeutic potential remain poorly defined. Using advanced approaches—including inducible genetic lineage tracing, single-cell RNA sequencing, and spatial transcriptomic profiling—we identified a population of Cd34+Pi16+ fibroblast progenitors (Cd34+ CAFs) in both melanoma and gastric cancer. We delineated their differentiation trajectory toward Acta2+ CAFs, driven by the upregulation of the transcription factor Foxs1. This work establishes the developmental origin of Acta2+ CAFs and experimentally validates the Cd34+ to Acta2+ transition. By reverse-matching the transcriptional signatures of Acta2+ CAF differentiation with the CMap/LINCS L1000 drug perturbation database, we identified four small-molecule candidates predicted to inhibit tumor-induced Foxs1 upregulation. These compounds effectively suppressed Cd34+ CAF differentiation, maintaining the progenitor-like Cd34+ state. Collectively, this study proposes a novel antitumor strategy that targets CAF lineage development to restrain tumor progression.